Introduction
Hepatitis is a type of inflammation occurring in the liver. Acute hepatitis can be self-limiting and progress to chronic hepatitis or it can lead to acute liver failure in rare instances (1) . Chronic hepatitis may progress to fibrosis, cirrhosis, or liver cancer. Hepatitis viruses are the most common cause of hepatitis around the world.
There are 5 major hepatitis viruses, types A, B, C, D, and E. These five types are of great significance because of their morbidity and mortality and their potential for causing outbreaks and spreading extensively (2) . Types B and C cause chronic liver disease in hundreds of millions of people worldwide, especially in Africa and Central and East Asia, and these 2 types are the most common cause of cirrhosis and liver cancer (3) . Although a few antivirals have been used to inhibit the hepatitis B virus, they also lead to obvious dosedependent adverse reactions and drug resistance (4) . Interferon-α (IFN-α) was the world's first medication to treat chronic hepatitis B virus (HBV) infection (5) . However, IFN-α does not yield satisfactory therapeutic outcomes and it leads to several adverse reactions such as flu-like syndrome, fatigue, drowsiness, and low blood counts (6) . Lamivudine, also called 3TC, was a major medication to treat HBV infection, but its therapeutic outcomes are also accompanied by a number of adverse reactions and it leads to drug resistance with longterm administration (7) . Recently, the most common therapy for chronic hepatitis C virus (HCV) has been IFN-α plus ribavirin. Both markedly inhibit the virus. However, both also cause various adverse reactions as well. Adverse reactions to IFN-α have previously been mentioned. Ribavirin is a major ribonucleic analog that is used to suppress HCV, but it often leads to a series of adverse reactions such as anemia, pain, fever, and trouble breathing (8, 9) . Besides these adverse events, most antivirals are costly. Therefore, novel drugs are urgently needed to treat HBV and HCV infection. Accordingly, alternative and complementary medicines (ACM) are being increasingly used. Traditional Chinese medicine (TCM), as a type of ACM, is a sophisticated and time-honored form of healthcare in China (10) . Many TCMs are widely used to treat hepatitis B in China and a number of other countries (11) . In China, TCM is used as CAM treatment and accounts for 30-50% of all medications used, with a low cost and low level of toxicity (12) . In the US, the 2002 National Health Interview Survey (NHIS) revealed that 19% of adults used some form of herbal medicine within the previous year (13) . TCMs are complicated mixtures of active compounds. Although the active compounds in TCMs have not been fully isolated and identified, a few have been found to be potential antivirals (14) . Bioactive compounds extracted from natural products have characteristics similar to chemically synthesized medications and they can be easily assimilated and metabolized by the human body (15) . Moreover, TCMs can be obtained from various organisms without the need for laborious or industrial chemosynthesis. Thus, TCMs could be a good candidate for antiviral development. Over the past few years, TCMs have garnered increasing attention from investigators searching for effective antiviral compounds.
Extracts in and formulations of TCMs to treat HBV
The effects of major extracts in and formulations of TCM to treat HBV infection, including Boehmeria nivea (Linn.) Gaudich, Polygonum cuspidatum, Stellaria media (L.) Vill., Ligularia atroviolacea, Radix Astragali, Oenanthe javanica, Xiao-Chai-Hu-Tang, Qizhu granules, FuZheng-Jie-Du-Tang, and cinobufacini, are summarized here. Research has mainly focused on cell experiments, animal experiments, and clinical trials. Anti-HBV activities of these formulations in preclinical experiments and clinical trials are listed in Table 1 .
Boehmeria nivea (Linn.) Gaudich is a type of perennial ratoon herbal plant, the root of which is used in TCM and possesses a number of pharmacological characteristics. A recent study found that the expression of hepatitis B virus surface antigen (HBsAg) and hepatitis B virus envelope antigen (HBeAg) decreased 328 contended that a combination of lamivudine and QZG would have therapeutic efficacy.
Several systematic reviews of TCM have reported that Fu-Zheng-Jie-Du-Tang (FZJDT) is able to inhibit HBV. FZJDT consists of a number of herbs, such as Cuscuta chinensis Lam., Eucommia ulmoides Oliver, and Poria cocos (Schw.) Wolf. He et al. designed a clinical trial in which three hundreds of patients infected with HBV were divided into a treatment group and control group. After 52 weeks of treatment, the treatment group had a more marked decrease in the mean concentration of serum HBsAg than the control group did. The treatment group had a significant increase in IFN-γ, suggesting that FZJDT was able to modulate host immune function (24) .
Cinobufacini, also known as Hua-Chan-Su, is a water-soluble extract made from toad skin (Bufo bufo gargarizans Cantor). Cinobufacini has long been used in China as an anti-tumor agent, an analgesic, an anti-inflammatory, and an anti-microbial. In a cell experiment, cinobufacini was reported to inhibit HBV replication by suppressing serum levels of HBsAg, HBeAg, hepatitis B core-related antigen (HBcrAg), and HBV DNA (25) . Results of a clinical trial by Yu et al. suggested that cinobufacini combined with IFN-2α 2b significantly inhibited HBV replication (26).
Bioactive compounds in TCMs to treat HBV
Although TCMs have facilitated drug development and clinical treatment, the full potential of those medicines has yet to tapped because of their complex composition and varying quality (27) . Over the past few years, rapid and substantial advances have been made in development of TCMs with the increasing emergence of novel theories, methods, techniques, and instruments (28) . Numerous bioactive compounds have been discovered in TCMs and their functions have been studied. A few bioactive compounds isolated from TCM have been reported to possess anti-HBV activity (29, 30) . The current review identified recent studies on bioactive compounds in TCMs with anti-HBV activity. These compounds have been found to be effective and warrant intensive study in the treatment of hepatitis B ( Table 2 ). The results of the studies in question have been classified into 4 findings: i) inhibiting the secretion of HBsAg, HBeAg, and/or HBcrAg; ii) inhibiting HBV DNA; iii) inhibiting both i) and ii); and iv) inhibiting HBV proliferation via other pathways.
i) Inhibiting the secretion of HBsAg, HBeAg, and/ or HBcrAg. A study by Dai et al., isolated 13 bioactive compounds from the TCM Viola diffusa Ging, and results suggested that 2β-hydroxy-3,4-seco-friedelolactone-27-oicacid,2β, 28β-dihydroxy-3,4-seco-friedelolactone-27-oicacid, and 2β,30β-dihydroxy-3,4-seco-friedelolactone- (16) .
Polygonum cuspidatum, also known as Hu-Zhang in China, is a type of TCM herb. P. cuspidatum which has a wide range of pharmacological effects, has been used to treat hot flashes, heart disease, cancer, and liver disease. An ethanol extract and resveratrol isolated from P. cuspidatum were found to be able to inhibit HBV at 10 μg/mL in vitro (17) .
Stellaria media (L.) Vill. is a TCM that has been used for hundreds years in China to mainly treat skin diseases, arthritis, and bronchitis. A study in HepG2.2.15 cells reported that 30 μg/mL of S. media effectively decreased the expression of HBsAg 27.92% and the expression of HBeAg 25.35% after administration for 6 days (18) .
Ligularia, also known as leopard plant, is a group of herbaceous perennial plants that is mainly distributed in the inland areas. Ligularia atroviolacea has been traditionally used as an herbal medicine to treat hepatitis B, asthma, hemoptysis, and pulmonary tuberculosis. Shi et al. reported that an ethyl acetate extract of L. atroviolacea inhibited the secretion of HBsAg in HepG2.
cells (19).
Radix Astragali is the dried root of Astragalus membranaceus (Fisch.) Bunge and Astragalus mongholicus Bunge (Fabaceae). Extracts of R. Astragali have been found to markedly decrease the concentration of HBeAg and HBV DNA in 116 clinical blood samples after 2 months of treatment and to inhibit levels of duck hepatitis B virus (DHBV) DNA in models of duck viral hepatitis B (20) .
The TCM Oenanthe javanica has been used to treat inflammation for many years in China. Han's research group used the HepG2.2.15 cell line and a model of DHBV infection to evaluate the anti-HBV effects of an ethanol extract of O. javanica. Results indicated that O. javanica suppressed HBsAg and HBeAg in vitro and that it also inhibited DHBV replication in duck models (21) .
Xiao-Chai-Hu-Tang (XCHT) has been widely used to treat various liver diseases in Asian countries. It consists of 7 different constituents, with Scutellariae radix accounting for most of its therapeutic effect. A study by Tseng et al. indicated that XCHT might inhibit HBV viral gene expression and DNA replication by regulating hepatic transcriptional machinery in vitro (22) .
Qizhu granules (QZG) are a TCM consisting of several herbs such as Astragalus. In a clinical trial, 103 patients with chronic hepatitis B were divided into 2 groups. All patients received lamivudine. The treatment group also received QZG. After 1 year of treatment, the treatment group tested positive for HBV DNA at the same rate as the control group, but the level of secreted HBeAg in the treatment group differed significantly from that in the control group (23) . Thus, the authors is a well-known TCM with a number of formulations that is used to treat hepatitis. Thirty-seven sesquiterpenoids were isolated from the fraction of C. rotundus using liquid chromatography-mass spectrometry (LC-MS). Six of those sesquiterpenoids may contribute to the anti-HBV activity of C. rotundus (32) . Plants of the genus Swertia (Gentianaceae), annual or perennial herbs, are thought to have hepatoprotective activity but whether they contained anti-HBV compounds was unclear. A study by Wang et al. found 3 new secoiridoids, swermacrolactones A-C, that were able to inhibit the expression of HBsAg and HBeAg in HepG2.2.15 cells with a 50% inhibitory concentration (IC 50 ) of 0.02 and 0.02 mM, respectively (33) . Piper longum Linn., a slender aromatic climber that is widely distributed in the world's tropical and subtropical areas, is used as a TCM. Recently, 11 active compounds were extracted from P. longum Linn. and 4 of those compounds were found to significantly inhibit the secretion of HBsAg and HBeAg in HepG2.2.15 cells (34) . Swertia macrosperma is a congeneric species of Swertia mileensis (Gentianaceae) that has been listed in the Chinese Pharmacopoeia (1977-2010 editions) because of its therapeutic effect on hepatitis B. In a recent study, 5 bioactive compounds, gentiocrucines A-E, were isolated from S. macrosperma and S. angustifolia, and those compounds were found to inhibit both the secretion of HBsAg and HBeAg in HepG2.2.15 cells, with an IC 50 of 3.14 and 3.35 mM (35) . A polyphenolic compound, 1,2,4,6-tetra-O-galloyl-β-D-glucose, was isolated from Phyllanthus emblica L. (Euphorbiaceae), and treatment with that TCM decreased levels of both HBsAg and HBeAg in the supernatant of cultured HepG2.2.15 cells (36) . Unlike the TCMs derived from herbs as have been mentioned thus far, bufalin and cinobufagin are active compounds that are derived from an animal source, the skin of Bufo bufo gargarizans Cantor (Bufonidae) (37) . A chemiluminescent enzyme immunoassay revealed that bufalin and cinobufagin effectively decreased the concentration of HBsAg, HBeAg, and HBcrAg in HepG2.2.15 cells in culture medium (27) .
ii) Inhibiting HBV DNA. Fifteen active compounds were isolated from Swertia delavayi using silica gel, Sephadex LH-20, and Rp-18 column chromatography (38) . Six of those compounds, aserythrocentaurin, iii) Inhibiting the secretion of HBsAg, HBeAg, and HBV DNA. The herb Rheum palmatum L. is a TCM that has been reported to be able to inhibit herpes simplex virus (HSV) and coxsackie virus (41) . Chrysophanol 8-O-β-D-glucoside, an active compound isolated from R. palmatum L., significantly inhibited HBV DNA replication and expression of viral antigens, with an IC 50 of 36.98 ± 2.28 μg/mL. An endogenous HBV DNA polymerase activity assay suggested that chrysophanol 8-O-β-D -glucoside might inhibit HBV DNA by suppressing DNA polymerase activity. Similarly, an active constituent, wogonin, from Scutellaria radix also was found to inhibit HBV DNA by inactivating DNA polymerase (42) . In HepG2.2.15 cells, wogonin effectively inhibited HBV antigen expression and DNA replication with an IC 50 of 4 μg/mL after 9 days of treatment. Wogonin decreased DHBV DNA, with an IC 50 of 0.57 μg/mL, in ducks infected with DHBV.
iv) Inhibiting HBV proliferation via other pathways. A new tricyclic polyketide, vanitaracin A, was part of a secondary metabolite pool extracted from a fungus, and vanitaracin A specifically inhibited HBV (43) . Vanitaracin A did not directly block the process of HBV replication. Instead, it interacted with sodium taurocholate cotransporting polypeptide (NTCP), an HBV entry receptor, and it disrupted its bile acid transport activity (44) . Vanitaracin A was similarly found to inhibit proliferation of the hepatitis D virus (HDV). Hydrocotyle sibthorpioides (Apiaceae) is a TCM used to treat inflammation and hepatitis B in China. An active compound, saponin, was isolated from H. sibthorpioides, and a study suggested that saponin would be able to decrease antigens in a culture medium containing HepG2.2.15 cells and that it would be able to inhibit DHBV DNA replication in ducks infected with HBV by suppressing the activity of core, s1, s2, and X gene promoters in the HBV genome (45) . Lamivudine-resistant strains of HBV have emerged with the widespread clinical use of lamivudine. Recently, two research teams respectively reported that cepharanthine hydrochloride and oxymatrine inhibited HBV proliferation by inhibiting heat stress cognate 70 (Hsc70), which is a host protein used for HBV replication (46, 47) .
Extracts in and formulations of TCMs to treat HCV
The ways in which major extracts in and formulations of TCMs, including Artemisia annua, Zingiberaceae, Galla Chinese, and Xiao-Chai-Hu-Tang, inhibit HCV infection are summarized here. Research has mainly focused on cell experiments and clinical trials. Anti-HCV activities of these extracts in and formulations in preclinical experiments and clinical trials are listed in Table 3 .
Artemisia annua, the dried aerial section of A. annua L. of the Compositae family, is a TCM that is used clinically to treat a fever or malaria and to enhancing immunity. Results of a study by Bao et al. suggested that an extract of A. annua, when used as an adjuvant of HCV/Nonstructural protein 3 (NS3) DNA vaccine, increased antibody levels in vivo and promoted IFN-γ secretion by increasing a Th1-type cellular immune response (48) . Galla chinensis, also called Wu-BeiZi, is a TCM that is commonly used to treat dysentery, bleeding, coughing, sweating, and rectal prolapse. An ethyl acetate (EtOAc) extract of G. Chinese was found to inhibit HCV proliferation by inhibiting NS3 protease, which is a 70-kDa cleavage product of the HCV polyprotein that acts as a serine protease (49) . In addition to drugs derived from herbs, drugs derived from animals also can inhibit HCV activity. Extracts from termite-associated bacteria were reported to inhibit bovine viral diarrhea virus (BVDV), which is used as a surrogate model for in vitro antiviral studies of HCV (50). Xiao-Chai-Hu-Tang (XCHT) is a formula consisting of 7 herbs that has been used to treat liver diseases in East Asia. In a phase II trial, XCHT was found to decrease levels of HCV (51) . However, the investigators cited several limitations of their trial, such as sampling bias, inter-observer variability, slow accrual, and a high dropout rate. Trial results also indicated that XCHT caused interstitial pneumonitis.
Bioactive compounds in TCMs to treat HCV
A number of bioactive compounds contained in TCMs have been found to act as HCV inhibitors. The current review identified recent studies on bioactive compounds in TCMs with anti-HCV activity. These compounds have been found to be effective and warrant intensive study in the treatment of hepatitis C ( Table 4 ). The results of the studies in question have been classified into 3 findings: i) inhibiting HCV entry; ii) inhibiting NS protein; and iii) other activities.
i) Inhibiting HCV entry. Entry is the first step for HCV to infect host cells. HCV entry into host hepatocytes is a complicated and multistep process that involves the HCV envelope glycoproteins E1 and E2 and several host factors like CD81 (52) . Thus far, several active compounds from TCM have been found to be able to interrupt the interaction between the HCV envelope proteins and receptors of host cells. Cynara cardunculus L. was used by Egyptians to treat diverse symptoms of hepatitis, such as jaundice and ascites. Two compounds isolated from C. cardunculus L., grosheimol and cynaropicrin, were studied for their anti-HCV activity (53) . Results indicated that these compounds inhibited HCV by suppressing HCV entry into host cells and that they blocked cell-free infection and cell-cell transmission. Calland et al. found that the flavonoids delphinidin and epigallocatechin-3-gallate (EGCG) (EGCG is found in green tea) inhibited HCV entry by changing the viral particle structure that facilitated HCV attachment to the host cell surface (54) . Similarly, a study by Lin et al. identified an active compound called saikosaponin b2, which was isolated from the TCM (58) . Similarly, another study found that an aqueous extract from Fructus Ligustri Lucidi blocked HCV entry by inhibiting NS5B viral RNA polymerase (59) . Except for NS5B polymerase, NS3 viral proteases have seldom been studied. Lee et al. reported that vitisin B, a resveratrol tetramer isolated from grapevine root, was able to inhibit HCV replication by binding to and suppressing NS3 in vitro and in vivo. A combination of vitisin B and sofosbuvir (an inhibitor of NS5B polymerase) had synergistic anti-HCV activity (60). Ashfaq et al. found that 3-Deacetyl-3-cinnamoylazadirachtin, isolated from Azadirachta indica, inhibited HCV by binding with NS3 protease and neutralizing it (61) . A study by Lan et al. revealed that honoliol, a compound derived from Magnolia, was able to block HCV infection by inhibiting NS3, NS5A, and NS5B (62) . According to that study, a combination of honoliol and interferon-α displayed synergistic anti-HCV activity.
iii) Other activities. In addition to inhibiting HCV entry, compounds also inhibit viral infection after entry. Ratnoglik et al. found that pheophorbide A and pyropheophorbide, two active compounds isolated from Morinda citrifolia, inhibited HCV infection by interrupting viral RNA replication and viral protein production (63) . Silybin B, a silymarin isolated from Silybum marianum, inhibited HCV infection in 2 ways (64). Silybin B was reported to inhibit HCV by decreasing HCV core proteins and it was also reported to increase antiviral efficacy by inhibiting major drugmetabolizing enzymes (CYP2C9, CYP3A4/5, and UDPglucuronsyltransferases).
Adverse reactions
Although TCMs and related compounds have been reported to be able to improve the efficacy of monotherapy or combination therapy for HBV and HCV, the adverse reactions caused by TCMs have not been discussed in-depth. A few studies have reported that some TCMs attenuate the adverse effects of chemotherapy or radiotherapy and produce fewer or no adverse reactions, but other studies have suggested that TCMs may cause obvious adverse reactions (65) (66) (67) . Kansui, the root of Euphorbia kansui T.N. Liou ex T.P. Wang, has been used as a remedy for edema, ascites, and asthma. According to one study, however, kansui affected cardiac and hepatic function and it affected the histomorphology of the heart, liver, and kidneys in rats (68) . The authors of a review concluded that the major adverse reactions to TCMs were gastrointestinal symptoms including abdominal bloating or pain, epigastric discomfort, and stomach disorder, followed by diarrhea, headaches, nausea, breast distension or pain, abnormal vaginal bleeding, and dizziness (69) . In a randomized controlled trial, Li et al. reported that Tongxinluo Capsules, a TCM used to treat coronary disease and angina pectoris, caused an adverse reaction in the form of stomachaches in the treatment group (70) . Berberine, an active compound extracted from the herb Berberis, may induce the onset of competitive junctional rhythm, causing a loss of atrioventricular synchronization, and reduce chronotropic competence with the onset of symptoms upon exertion (71) . In fact, the present evidence of adverse reactions and toxicity is insufficient. There are a few obstacles to evaluating adverse reactions: i) experimental data is limited to pharmacokinetics and inaccurate clinical research, ii) only a few studies have documented target organ toxicity, and iii) the evidence is not sufficient to elucidate the biochemical mechanisms responsible for the biological activities of TCMs. Thus, further studies are needed to study the pharmacokinetics and features of TCMs and their active compounds, and comprehensive and accurate data should be collected through clinical trials. Furthermore, mechanisms causing adverse reactions to TCMs need to be explored in depth.
Conclusion
Hepatitis is a severe liver disease leading to chronic hepatitis, acute liver failure, or hepatocellular carcinoma. Two pathogens that predominantly cause hepatitis are HBV and HCV. Conventional medications cause adverse effects and are costly, so TCMs and related bioactive compounds are garnering attention as CAM. This review has summarized the TCMs and active compounds used to treat HBV and HCV. Several points have become evident from this review: i) HepG2.2.15 is a generally accepted cell line for anti-HBV research in vitro; ii) ducks are used as animal model for DHBV infection to study anti-HBV activity in vivo; iii) Hun7.5 is a cell line that is often used in anti-HCV research in vitro; iv) there are few animal models for anti-HCV research in vivo; v) in addition to TCMs and compounds derived from herbs, compounds derived from animals are also used to inhibit HCV infection and have yielded desired results; vi) a few therapies combining compounds and medications have yielded satisfactory results; vii) thus far, few clinical trials have been conducted on active compounds; viii) limited basic studies thus far have yet to elucidate the mechanisms of antiviral action of TCMs; ix) several chemically modified bioactive compounds have displayed more effective antivirus activity than natural products. Several steps need to be taken in future work on treatments for HBV and HCV infections. More bioactive compounds from TCMs need to be explored, new animal models need to be created for anti-HCV research, novel chemically modified bioactive compounds need to be developed, clinical trials need to be conducted, and the molecular mechanisms of action of TCMs need to be elucidated.
